TIER-1 ENDOSURE Test
Empowering You to Diagnose Endometriosis at First Patient Visit
TIER-1 DIAGNOSTIC SUPPORT
- 99% accuracy, 95% sensitivity, 96% specificity
- Testing takes less than an hour and provides instant results
- Detects all disease stages
- Auto-diagnostic & self calibrating
PATIENT CENTRED EXPERIENCE
- For all ages, premenarche to post menopause
- Painless & trauma informed
- Minimal patient preparation
- Patients remain fully clothed during test
CLINICAL FIT
- Manufacturer Certified Training for your staff
- No special equipment required beyond ENDOSURE System
- No biological sample collection or disposal required
ENDOSURE provides clinical evidence for practitioners who suspect endometriosis
Non-invasive Endometriosis GIMA Biomarker Screening
ENDOSURE is an accurate yet non-invasive diagnostic test for endometriosis. The ENDOSURE test uses an electroviscerography system (EVG), an analytical instrument that collects Gastro Intestinal Myoelectrical Activity (GIMA) signals from the abdomen through dry electrodes. The test detects endometriosis presence by measuring a GIMA pattern unique to endometriosis sufferers, known as the GIMA biomarker. Very similar to an electrocardiogram/EKG it’s easy to perform and provides a near-instant diagnostic result using simple, objective GIMA data.
ENDOSURE provides clinical evidence for practitioners who suspect endometriosis in their patients with:
- Dysmenorrhea and/or chronic pelvic pain
- Infertility & miscarriage
- Screening in pre-pregnancy. Endometriosis is associated with higher-risk for placenta previa, preeclampsia, preterm birth and post-partum hemorrhage.
Information for Providers
View the Research
Talk to Us
Contact us to learn more and bring endosure testing to your patients.
ENDOSURE, the only Tier 1 test for endometriosis
The Science
Endometriosis causes unusual contractile patterns in the small bowel due to higher than normal serum levels of prostaglandins secreted by endometriosis tissues, despite disease location; peritoneal, ovarian, extra pelvic or intrauterine. While normal ranges of gut contractions are 1-12 cycles per minute (CPM) in healthy women, prostaglandins cause uncontrolled high-frequency contractions ranging from 15-200 CPM when endometriosis is present. This causes many of the painful symptoms associated with endometriosis.
The ENDOSURE Test objectively collects this gut seizure activity using EVG, then compares a patient’s GIMA profile to the “GIMA biomarker” for endometriosis to detect disease presence. In clinical studies, the test has 99% accuracy (98% accuracy for patients 36 years+) in surgically verified studies, reflecting a strong ability to distinguish between positive and negative cases.1
ENDOSURE test results offer clinical decision support, when endometriosis is suspected. With testing more like an ECG, Tier 1 diagnostic testing for endometriosis is now fast, easy, safe and accurate.
Tier 1 Diagnostic Test for Endometriosis – results in 30 minutes
How it works
Electroviscerography system (EVG) is an analytical instrument that collects myoelectrical activity signals from your gastrointestinal tract (GIMA).
The ENDOSURE test records the GIMA pattern. This data is analyzed, then compared to the GIMA biomarker, a known digital “fingerprint” of people who suffer from endometriosis.2,3
The near-instant results of this rapid, pain free and non-invasive diagnostic test supports your diagnosis of endometriosis and expedites the the process for treatment and management of the disease.
What Clinicians are Saying
“We’ve not seen any real movement in the treatments and the diagnosis of endometriosis for like two decades and now it’s all seems to be coming together. It’s a combination of the ENDOSURE test and the new drugs, which is going to change the management for many of these young women.”
- Dr. David Griffiths, Consultant Gynaecologist MB ChB, FRCOG
“ Until now we haven’t had a very good, simple, easy, quick, inexpensive screening test for endometriosis. Until now the only way to diagnose endometriosis definitively has been with a surgical procedure. Still to this day, the average time from onset of symptoms to diagnosis is anywhere from 7 to 12 years. And the average woman who has these symptoms sees anywhere from seven to 10 different doctors before they get a diagnosis. We have the potential to crack that nut.
Larry Glazerman, MD, MBA
“If patients understand why they’re experiencing symptoms, it helps them cope, reduces stress, and creates closure so they can move forward with appropriate treatment. ENDOSURE testing provides that clarity in minutes rather than years.”
-Dr. Sarah Roth, ND
Abstract Presentation, IIRRM Congress 2025, Zagreb, Croatia
LAtest Research
Abstract Title: Gastrointestinal Myoelectrical Activity (GIMA) Biomarker Accurately Determines Presence of Absence of Endometriosis
Presented by Maria Bizecki-Porcellato, BSP, ACPR, CFCP, CFCPh.
Confirming research for the ENDOSURE test was presented as an Abstract in Zagreb, Croatia at the 2025 RRM Congress. This research was significant, as the 340 patient set validated the ENDOSURE test used in a real world experience. Key findings include a sensitivity of 95%, a specificity of 86%, and a diagnostic accuracy of 92%.
Oral Abstract Presentation, AAGL 2025, Vancouver, BC, Canada
Validating Research
Abstract Title: Defining the role of the gastrointestinal myoelectrical activity (GIMA) biomarker in the diagnosis of endometriosis
Authors: P Tanos, F Donders, A Massaro, S Philippe, S Karampelas
CHU Bruggman, Brussels, validated GIMA v. MRI (35 patients), TV-US (45 patients) and laparoscopy (12 patients) using #Enzian classification. Sensitivity 100%, specificity of 5%, diagnostic accuracy of 96% in detecting both deep and superficial endometriosis (preliminary data, May 2025). Notably, GIMA biomarkers identified superficial endometriosis in cases missed by conventional imaging. Additionally, 60% of patients preferred ENDOSURE over TV-US.
Tanos P, Donders F, Massaro A, Philippe S, Karampelas S. Defining the role of the gastrointestinal myoelectrical activity (GIMA) biomarker in the diagnosis of endometriosis. J Minim Invasive Gynecol. 2025;32(11)(suppl):S23. doi:10.1016/j.jmig.2025.09.027.
Oral Presentation #2, AAGL 2025, Vancouver, BC, Canada
Abstract Title: Non-Invasive Electroviscerography for the Diagnosis of Endometriosis: A Prospective Pilot Study
Authors: Marina P Andres, MD , Ana Clara P Servidoni , Ana Luiza B Luduwig , Lara L Passos , Mariana M Brunoro and Mauricio S Abrao, MD
Findings: Compared to laparoscopy (n=13) of 43 women, EVG showed sensitivity 100%, specificity 0%, accuracy 92.31%. Compared to TVUS (n=30) EVG showed sensitivity 81.28%, specificity 26.32%, accuracy 46.67%
Published Research:
Mark Noar, John Mathias, Ajit Kolatkar. Validation of New GIMA Biomarker Signature of Endometriosis – Interim Data: Research Article. Advance. August 26, 2024.
DOI: 10.22541/au.172469630.08159498/v1
Noar M, Mathias J, Kolatkar A. Gastrointestinal Myoelectrical Activity (GIMA) Biomarker for Noninvasive Diagnosis of Endometriosis. J Clin Med. 2024;13(10):2866. Published 2024 May 13. doi:10.3390/jcm13102866
AI-Derived Threshold Score of Intraabdominal Myoelectrical Activity Predicts Presence and Stage of Endometriosis with 100% Accuracy, Noar, M., Journal of Minimally Invasive Gynecology, Volume 29, Issue 11, S4 – S5. DOI: 10.1016/j.jmig.2022.09.026
4. Tanos P, Donders F, Massaro A, Philippe S, Karampelas S. Defining the role of the gastrointestinal myoelectrical activity (GIMA) biomarker in the diagnosis of endometriosis. J Minim Invasive Gynecol. 2025;32(11)(suppl):S23. doi:10.1016/j.jmig.2025.09.027
